Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors - Shah, A.Y.; Kotecha, R.R.; Lemke, E.A.; Chandramohan, A.; Chaim, J.L.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M.T.; Zurita, A.J.; Wang, J.; Corn, P.G.; et al. (European journal of cancer (1990), 2019)
Keywords: Anticancer properties; Apoptosis; Bevacizumab; Cancer; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - mortality; Carcinoma, Renal Cell - pathology; ccRCC; Clear cell renal cell carcinoma; Clear cell-type renal cell carcinoma; Confidence intervals; Consortia; Enzyme inhibitors; Female; Growth factors; Health risks; Humans; Immune checkpoint inhibitor; Immune checkpoint inhibitors; Immunological tolerance; Immunotherapy; Immunotherapy - methods; Immunotherapy refractory; Inhibitors; Kidney cancer; Kidney Neoplasms - drug therapy; Kidney Neoplasms - mortality; Kidney Neoplasms - pathology; Kinases; Male; Median (statistics); Metastases; Metastasis; Metastatic kidney cancer; Middle Aged; Monoclonal antibodies; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase receptors; RCC; Renal cell carcinoma; Retrospective Studies; Risk; Solid tumors; Statistical analysis; Survival; Survival Analysis; Targeted cancer therapy; Therapy; Therapy sequence; Toxicity; Treatment Outcome; Tumors; Tyrosine; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Vascular endothelial growth factor receptors; VEGFR-TKI; RCC; ccRCC; Therapy sequence; Immune checkpoint inhibitor; Renal cell carcinoma; Immunotherapy; Clear cell renal cell carcinoma; Immunotherapy refractory; VEGFR-TKI; Metastatic kidney cancer